Jokath (Timolol, Travoprost)

Timolol reduces the production of aqueous humor by blocking β‑adrenergic receptors in the ciliary body, while travoprost increases uveoscleral outflow of aqueous humor as a prostaglandin F2α analog. Together they achieve a complementary reduction in intra‑ocular pressure.

The dosing regimen for Jokath is determined by the prescribing clinician based on the patient’s condition, response, and tolerance. Typically, one drop is instilled in the affected eye(s) once daily, but the exact schedule should follow the prescriber’s instructions.

Safety data for Jokath in pregnancy and lactation are limited. It should be used only if the potential benefit outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Jokath, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jokath combines a beta‑blocker (timolol) and a prostaglandin analog (travoprost) in a single formulation, offering dual mechanisms of action. This can simplify treatment compared with using separate agents, potentially improving adherence while delivering comparable intra‑ocular pressure reduction to other combination therapies.

Jokath should be stored at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed in its original packaging until use, and discard any solution that appears discolored or contaminated.

Jokath is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and place one drop into the conjunctival sac of the affected eye(s). Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks include severe allergic reactions, significant eye pain or sudden loss of vision, and systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm. Patients should seek immediate medical attention if any of these symptoms occur.

Jokath is contraindicated in patients with known hypersensitivity to timolol, travoprost, or any component of the formulation. It should also be avoided in individuals with severe asthma, untreated cardiac conduction disorders, or those using non‑selective systemic beta‑blockers without medical supervision.